The global blood culture test market size reached US$ 5.1 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 9.9 Billion by 2032, exhibiting a growth rate (CAGR) of 7.65% during 2023-2032. The rising incidences of bacterial and fungal infections among individuals, the increasing prevalence of hospital-acquired infections (HAIs), and the emerging advancements in diagnostic technology are some of the major factors contributing to the market growth.
Furthermore, various key market players are introducing advanced diagnostic solutions to tackle the bolstering number of diagnoses. For instance, according to the study article published in May 2022 in Scientific Reports, a machine learning model was constructed for COVID-19 diagnosis based and cross-validated on the routine blood test of 5,333 patients with various bacterial and 160 patients having COVID-19 infections. Such innovations to handle the escalating cases of bacterial and fungal infections are anticipated to catalyze blood culture test market growth in the coming years.
The Increasing Prevalence of Hospital-Acquired Infections (HAIs)
HAIs are infections that patients acquire while receiving treatment for other conditions within healthcare facilities. The increasing numbers of patients in hospital stays are leading to escalating cases of HIAs, which in turn is bolstering the market for blood culture tests. Additionally, according to the WHO, nearly 235 million major surgical procedures are performed every year. The Centers for Disease Control and Prevention issued a Healthcare Associated Infection Progress Report 2020, which indicated that there were nearly 18,416 surgical site infections reported in 2020 in the United States.
It also reported that out of this, 6,094 infections were during colon surgery, and 2,173 occurred during hip arthroplasty. Such a surge in hospital-acquired infections is catalyzing the need for robust blood culture tests. Moreover, blood culture tests are essential in diagnosing and monitoring infectious diseases, thus escalating the demand for these tests with the growing number of HAI rates.
Similarly, in June 2023, Sun Pharmaceutical Industries announced an increase in R&D investment in specialty and generics businesses. According to the firm, its current generics pipeline for the US market includes 97 ANDAs, while 13 new drug applications are awaiting the U.S. FDA's approval. In addition to this, various concerned regulatory authorities are also taking initiatives to enhance diagnostics, which is creating a positive outlook for the overall market. For instance, the Centers for Medicare & Medicaid Services (CMS) is a regulatory body in North America that monitors and regulates all laboratory testing performed on humans in the U.S.
through the Clinical Laboratory Improvement Amendments (CLIA), which includes 260,000 laboratory entities. Besides this, the integration of artificial intelligence (AI) and machine learning (ML) algorithms into blood culture analysis is enabling a quick analysis of vast datasets and predicting outcomes. This, in turn, assists healthcare professionals in making informed decisions.
Conventional tests are employed in hospitals, clinics, and healthcare facilities across the globe. They serve as a fundamental diagnostic tool to identify the presence of bacteria, fungi, or other microorganisms in the bloodstream of the patient. Moreover, as these tests are essential for physicians to identify the appropriate course of treatment, various key market players are launching technologically advanced blood tests.
For instance, in January 2022, Eurofins subsidiary empowerDX launched PFAS Exposure in the United States, a direct-to-consumer at-home test to determine levels of per- and polyfluorinated alkyl substances (PFAS) in a person's blood and measure 47 of the PFAS chemical compounds. Besides this, conventional tests are reliable, providing healthcare professionals with a well-established and trusted method for detecting bloodstream infections. This level of reliability is augmenting the demand for conventional tests.
Consumables are employed at various essential junctures in the blood culture process. According to the American Cancer Society's 2022 statistics, there were approximately 1,918,030 new cases of cancer in the United States in 2022. Such an increasing burden of diseases such as cancer creates the need for precision medicine, which leads to the increase in demand for cell culture products and consumables for their development and hence drives the growth of the market.
Moreover, various leading market players are increasingly focusing on research and development activities to develop improved cell culture products. For instance, in February 2022, KromaTiD launched a comprehensive suite of cell and blood culture growth, isolation, processing, and quality control services. The launch of such products and services by the companies also boosts the demand for cell culture products and consumables and is thus expected to drive the growth of this segment.
Culture-based technology allows for the detection and identification of microbial pathogens, such as bacteria and fungi, in the blood samples of patients, which is essential in diagnosing bloodstream infections (BSIs) that can be life-threatening. As a result, various key companies are extensively investing in research activities to enhance culture-based technology. For instance, in June 2022, Evonik launched the cQrex portfolio of cell culture ingredients to increase efficiency and productivity in bioprocesses for producing monoclonal antibodies, vaccines, viral vectors, and therapeutic cells.
Similarly, in February 2022, CellulaREvolution raised GBP 1.75 Million to accelerate the launch of its continuous cell culture technology. Furthermore, culture-based technology offers a high level of sensitivity. It can distinguish between several strains of microorganisms, allowing healthcare providers to customize their treatment strategies accordingly.
Bacterial infections are a prevalent concern in the healthcare sector. These infections can manifest in various forms, from mild to severe, and often require timely and accurate diagnosis for effective treatment. As a result, various healthcare institutions and pharmaceutical companies are increasingly investing in robust blood culture testing solutions.
For instance, in June 2022, Basilea Pharmaceutica Ltd announced positive topline results for the Phase III ERADICATE study, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcus aureus (SAB). Similarly, in May 2022, Nabriva Therapeutics PLC agreed to extend its exclusive agreement with subsidiaries of Merck & Co. Inc.
to promote and distribute SIVEXTRO (tedizolid phosphate, an antibiotic of the oxazolidinone class used to treat acute bacterial skin and skin structure infections (ABSSSI)) in the United States through December 31, 2026. Furthermore, the continuous advancements in technology improved the sensitivity and specificity of these tests, making them more reliable in detecting bacterial infections accurately.
Hospital laboratories are equipped with advanced technology and several resources, enabling them to conduct tests with a high degree of accuracy and efficiency. These laboratories often deliver more reliable results compared to other laboratories, due to which hospital laboratories are the go-to choice for healthcare professionals. Various healthcare facilities are investing in the establishment and expansion of advanced hospital laboratories. For instance, in September 2021, the Indian division of Roche Diagnostics launched the Cobas pure integrated solutions analyzer with an advanced system suitable for many labs and hospitals operating in the country.
The North American market is driven by the growing healthcare infrastructure that includes numerous networks of hospitals, clinics, and laboratories. Furthermore, the presence of a well-established healthcare insurance system in the region, ensuring that a substantial portion of the population has access to medical services, including blood culture testing, is also contributing to the region's growth. Additionally, the launch of technologically advanced blood tests in the United States will also positively impact the market growth.
For instance, in January 2022, Eurofins subsidiary empowerDX launched PFAS Exposure in the United States, the direct-to-consumer at-home test to determine levels of Per- and Polyfluorinated Alkyl Substances (PFAS) in a person's blood and measure 47 of the PFAS forever chemical compounds. In addition to this, in August 2021, Smart Meter launched the glucose monitor for managing gestational diabetes.
It provides an easy and reliable way to test, monitor, and manage blood glucose levels, ensuring that all care providers have immediate access to testing results. Moreover, regulatory bodies in North America maintain rigorous standards for healthcare products and services, which instill confidence in tests, making them a preferred choice for healthcare professionals and patients.
2. What is the expected growth rate of the global blood culture test market during 2024-2032?
3. What are the key factors driving the global blood culture test market?
4. What has been the impact of COVID-19 on the global blood culture test market?
5. What is the breakup of the global blood culture test market based on the testing method?
6. What is the breakup of the global blood culture test market based on the product?
7. What is the breakup of the global blood culture test market based on technology?
8. What is the breakup of the global blood culture test market based on the application?
9. What is the breakup of the global blood culture test market based on the end user?
10. What are the key regions in the global blood culture test market?
11. Who are the key players/companies in the global blood culture test market?
Global Blood Culture Test Market Analysis:
- Major Market Drivers: The increasing prevalence of infectious diseases such as sepsis, bloodstream infections, and bacterial infections is primarily driving the market growth. In addition to this, the rising demand for accurate diagnostic methods is also leading to the increased adoption of blood culture tests to identify the causative agents of these infections. This guides physicians in prescribing appropriate treatments and reducing mortality rates.
- Key Market Trends: Ongoing advancements in blood culture testing technologies, such as automated systems, molecular diagnostics, and rapid detection methods, are enhancing the accuracy and efficiency of these tests, which is acting as a primary key trend for the market growth.
- Geographical Trends: According to the report, North America accounted for the largest market share. The growth in this region is driven by the growing healthcare infrastructure that includes numerous networks of hospitals, clinics, and laboratories. Furthermore, the presence of a well-established healthcare insurance system in the region is also contributing to the region's growth.
- Competitive Landscape: Some of the blood culture test market leaders are Abbott Laboratories, Danaher Corporation, Becton, Dickinson and Company, bioMeriux SA, Bruker Corporation, Luminex Corporation, Merck KGaA, Siemens Healthcare GmbH, F.Hoffmann-La Roche Ltd., T2 Biosystems Inc., Thermo Fisher Scientific Company, among others.
- Challenges and Opportunities: One of the prominent challenges in the blood culture test market is quality control and standardization. Ensuring consistent quality and standardization across different laboratories and regions is challenging. However, many companies are developing and implementing automated blood culture systems and standardized equipment. Automation reduces human error and variability in handling and processing samples. Standardized equipment ensures consistent conditions and protocols are used across different testing sites. This in turn is anticipated to augment the blood culture test market share in the coming year.
Blood Culture Test Market Trends:
The Rising Incidences of Bacterial and Fungal Infections
The escalating number of bacterial and fungal infections and a growing geriatric population are primarily driving the growth of the blood culture test market. According to the European Centre for Disease Prevention and Control's January 2023 publication, up to December 31, 2022, 4,110,465 cases of dengue and 4,099 deaths were reported. As a result, early detection of disease progression associated with severe dengue is bolstering the demand for blood testing for timely diagnosis of the diseases, thus driving the market. Early detection of disease progression associated with severe dengue and access to proper medical care can lower fatality rates of severe dengue to below 1%.Furthermore, various key market players are introducing advanced diagnostic solutions to tackle the bolstering number of diagnoses. For instance, according to the study article published in May 2022 in Scientific Reports, a machine learning model was constructed for COVID-19 diagnosis based and cross-validated on the routine blood test of 5,333 patients with various bacterial and 160 patients having COVID-19 infections. Such innovations to handle the escalating cases of bacterial and fungal infections are anticipated to catalyze blood culture test market growth in the coming years.
The Increasing Prevalence of Hospital-Acquired Infections (HAIs)
HAIs are infections that patients acquire while receiving treatment for other conditions within healthcare facilities. The increasing numbers of patients in hospital stays are leading to escalating cases of HIAs, which in turn is bolstering the market for blood culture tests. Additionally, according to the WHO, nearly 235 million major surgical procedures are performed every year. The Centers for Disease Control and Prevention issued a Healthcare Associated Infection Progress Report 2020, which indicated that there were nearly 18,416 surgical site infections reported in 2020 in the United States.
It also reported that out of this, 6,094 infections were during colon surgery, and 2,173 occurred during hip arthroplasty. Such a surge in hospital-acquired infections is catalyzing the need for robust blood culture tests. Moreover, blood culture tests are essential in diagnosing and monitoring infectious diseases, thus escalating the demand for these tests with the growing number of HAI rates.
The Emerging Advancements in Diagnostic Technology
The increasing adoption of automated blood culture systems, which use advanced edge sensors and software algorithms to detect microbial growth in blood samples more rapidly and precisely than traditional methods, is acting as another significant growth-inducing factor for the market. Various key market players are extensively investing in research and development activities to introduce robust automated blood testing technologies. For instance, in December 2022, InsilicoMedicine launched Life Star, which was the 6th generation Intelligent Robotics Drug Discovery Laboratory. The fully automated AI-powered robotics laboratory performs target discovery, precision medicine development, compound screening, and translational research.Similarly, in June 2023, Sun Pharmaceutical Industries announced an increase in R&D investment in specialty and generics businesses. According to the firm, its current generics pipeline for the US market includes 97 ANDAs, while 13 new drug applications are awaiting the U.S. FDA's approval. In addition to this, various concerned regulatory authorities are also taking initiatives to enhance diagnostics, which is creating a positive outlook for the overall market. For instance, the Centers for Medicare & Medicaid Services (CMS) is a regulatory body in North America that monitors and regulates all laboratory testing performed on humans in the U.S.
through the Clinical Laboratory Improvement Amendments (CLIA), which includes 260,000 laboratory entities. Besides this, the integration of artificial intelligence (AI) and machine learning (ML) algorithms into blood culture analysis is enabling a quick analysis of vast datasets and predicting outcomes. This, in turn, assists healthcare professionals in making informed decisions.
Blood Culture Test Industry Segmentation:
The publisher provides an analysis of the key trends in each segment of the global blood culture test market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on testing method, product, technology, application, and end user.Breakup by Testing Method:
- Conventional
- Automated
Conventional testing represents the most popular method used
Conventional tests are employed in hospitals, clinics, and healthcare facilities across the globe. They serve as a fundamental diagnostic tool to identify the presence of bacteria, fungi, or other microorganisms in the bloodstream of the patient. Moreover, as these tests are essential for physicians to identify the appropriate course of treatment, various key market players are launching technologically advanced blood tests.
For instance, in January 2022, Eurofins subsidiary empowerDX launched PFAS Exposure in the United States, a direct-to-consumer at-home test to determine levels of per- and polyfluorinated alkyl substances (PFAS) in a person's blood and measure 47 of the PFAS chemical compounds. Besides this, conventional tests are reliable, providing healthcare professionals with a well-established and trusted method for detecting bloodstream infections. This level of reliability is augmenting the demand for conventional tests.
Breakup by Product:
- Consumables
- Blood Culture Media
- Aerobic Blood Culture Media
- Anaerobic Blood Culture Media
- Fungi/Yeast Blood Culture Media
- Mycobacteria Blood Culture Media
- Assay Kits and Reagents
- Blood Culture Accessories
- Instruments
- Automated Blood Culture Systems
- Supporting Laboratory Equipment
- Incubators
- Colony Counters
- Microscopes
- Gram Stainers
- Software and Services
Consumables are employed at various essential junctures in the blood culture process. According to the American Cancer Society's 2022 statistics, there were approximately 1,918,030 new cases of cancer in the United States in 2022. Such an increasing burden of diseases such as cancer creates the need for precision medicine, which leads to the increase in demand for cell culture products and consumables for their development and hence drives the growth of the market.
Moreover, various leading market players are increasingly focusing on research and development activities to develop improved cell culture products. For instance, in February 2022, KromaTiD launched a comprehensive suite of cell and blood culture growth, isolation, processing, and quality control services. The launch of such products and services by the companies also boosts the demand for cell culture products and consumables and is thus expected to drive the growth of this segment.
Breakup by Technology:
- Culture-based Technology
- Molecular Technology
- Microarray
- PCR
- PNA-FISH
- Proteomic Technology
- Others
Culture-based technology holds the largest share of the market
Culture-based technology allows for the detection and identification of microbial pathogens, such as bacteria and fungi, in the blood samples of patients, which is essential in diagnosing bloodstream infections (BSIs) that can be life-threatening. As a result, various key companies are extensively investing in research activities to enhance culture-based technology. For instance, in June 2022, Evonik launched the cQrex portfolio of cell culture ingredients to increase efficiency and productivity in bioprocesses for producing monoclonal antibodies, vaccines, viral vectors, and therapeutic cells.
Similarly, in February 2022, CellulaREvolution raised GBP 1.75 Million to accelerate the launch of its continuous cell culture technology. Furthermore, culture-based technology offers a high level of sensitivity. It can distinguish between several strains of microorganisms, allowing healthcare providers to customize their treatment strategies accordingly.
Breakup by Application:
- Bacterial Infections
- Fungal Infections
- Mycobacterial Infections
Bacterial infections presently account for the largest market share
Bacterial infections are a prevalent concern in the healthcare sector. These infections can manifest in various forms, from mild to severe, and often require timely and accurate diagnosis for effective treatment. As a result, various healthcare institutions and pharmaceutical companies are increasingly investing in robust blood culture testing solutions.
For instance, in June 2022, Basilea Pharmaceutica Ltd announced positive topline results for the Phase III ERADICATE study, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcus aureus (SAB). Similarly, in May 2022, Nabriva Therapeutics PLC agreed to extend its exclusive agreement with subsidiaries of Merck & Co. Inc.
to promote and distribute SIVEXTRO (tedizolid phosphate, an antibiotic of the oxazolidinone class used to treat acute bacterial skin and skin structure infections (ABSSSI)) in the United States through December 31, 2026. Furthermore, the continuous advancements in technology improved the sensitivity and specificity of these tests, making them more reliable in detecting bacterial infections accurately.
Breakup by End User:
- Hospital Laboratories
- Reference Laboratories
- Research Laboratories
- Others
Hospital laboratories hold the largest share of the market
Hospital laboratories are equipped with advanced technology and several resources, enabling them to conduct tests with a high degree of accuracy and efficiency. These laboratories often deliver more reliable results compared to other laboratories, due to which hospital laboratories are the go-to choice for healthcare professionals. Various healthcare facilities are investing in the establishment and expansion of advanced hospital laboratories. For instance, in September 2021, the Indian division of Roche Diagnostics launched the Cobas pure integrated solutions analyzer with an advanced system suitable for many labs and hospitals operating in the country.
Breakup by Region:
- North America
- United States
- Canada
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
North America exhibits a clear dominance in the market
The North American market is driven by the growing healthcare infrastructure that includes numerous networks of hospitals, clinics, and laboratories. Furthermore, the presence of a well-established healthcare insurance system in the region, ensuring that a substantial portion of the population has access to medical services, including blood culture testing, is also contributing to the region's growth. Additionally, the launch of technologically advanced blood tests in the United States will also positively impact the market growth.
For instance, in January 2022, Eurofins subsidiary empowerDX launched PFAS Exposure in the United States, the direct-to-consumer at-home test to determine levels of Per- and Polyfluorinated Alkyl Substances (PFAS) in a person's blood and measure 47 of the PFAS forever chemical compounds. In addition to this, in August 2021, Smart Meter launched the glucose monitor for managing gestational diabetes.
It provides an easy and reliable way to test, monitor, and manage blood glucose levels, ensuring that all care providers have immediate access to testing results. Moreover, regulatory bodies in North America maintain rigorous standards for healthcare products and services, which instill confidence in tests, making them a preferred choice for healthcare professionals and patients.
Competitive Landscape:
The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the blood culture test top companies include:
- Abbott Laboratories
- Danaher Corporation
- Becton, Dickinson and Company
- bioMeriux SA
- Bruker Corporation
- Luminex Corporation
- Merck KGaA
- Siemens Healthcare GmbH
- F.Hoffmann-La Roche Ltd.
- T2 Biosystems Inc.
- Thermo Fisher Scientific Company
Global Blood Culture Test Market News:
- November 2023: In observance of World AMR Awareness Week (WAAW), Magnolia Medical Technologies, Inc., the inventors of the Steripath Initial Specimen Diversion Device (ISDD), is leading the way to show how important it is to use diagnostics wisely to fight against the danger of antimicrobial resistance (AMR).
- March 2023: Brooks Automation US, LLC announced the acquisition of Aim Lab Automation Technologies Pty Ltd. to expand solutions within the lab automation segment. This acquisition further expanded Brooks' presence beyond drug discovery into the clinical diagnostics market. Moreover, Aim Lab, in collaboration with PreciseFlex, will provide a broader set of capabilities and an expanded global presence to its customers.
- October 2022: BD (Becton, Dickinson, and Company), a leading global medical technology company, and Magnolia Medical Technologies, Inc., announced a co-exclusive commercial agreement aimed at helping U.S. hospitals reduce blood culture contamination to help improve testing accuracy and ultimately improve clinical outcomes.
Key Questions Answered in This Report
1. What was the size of the global blood culture test market in 2023?2. What is the expected growth rate of the global blood culture test market during 2024-2032?
3. What are the key factors driving the global blood culture test market?
4. What has been the impact of COVID-19 on the global blood culture test market?
5. What is the breakup of the global blood culture test market based on the testing method?
6. What is the breakup of the global blood culture test market based on the product?
7. What is the breakup of the global blood culture test market based on technology?
8. What is the breakup of the global blood culture test market based on the application?
9. What is the breakup of the global blood culture test market based on the end user?
10. What are the key regions in the global blood culture test market?
11. Who are the key players/companies in the global blood culture test market?
Table of Contents
1 Preface3 Executive Summary13 Value Chain Analysis
2 Scope and Methodology
4 Introduction
5 Global Blood Culture Test Market
6 Market Breakup by Testing Method
7 Market Breakup by Product
8 Market Breakup by Technology
9 Market Breakup by Application
10 Market Breakup by End-User
11 Market Breakup by Region
12 SWOT Analysis
14 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Danaher Corporation
- Becton
- Dickinson
- Company
- bioMeriux SA
- Bruker Corporation
- Luminex Corporation
- Merck KGaA
- Siemens Healthcare GmbH
- F.Hoffmann-La Roche Ltd.
- T2 Biosystems Inc.
- Thermo Fisher Scientific Company
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 148 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 5.1 Billion |
| Forecasted Market Value ( USD | $ 9.9 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
